All In Biotech

Drug Trial Radar · NCT04341454

Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Acute or Chronic Gastritis

A Multi-Center, Double-blind, Randomized, Placebo-controlled, Parallel-Group, Phase 3, Therapeutic Confirmatory Clinical Trial to Evaluate the Efficacy and Safety of DWP14012 in Patients With Acute or Chronic Gastritis

Last checked: Nov 19, 2026Latest source record: Dec 21, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 327 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

327

Actual

Start

Jun 2, 2020

Primary completion

Aug 4, 2021

Study completion Sep 16, 2021

Sponsor

Sponsor type
Industry
First posted
Apr 10, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of study is to confirm the efficacy of DWP14012 X mg QD, DWP14012 Y mg BID compared to placebo in patients with Acute or Chronic Gastritis

Conditions

  • Acute Gastritis
  • Chronic Gastritis

Interventions

  • DWP14012 X mgDrug

    DWP14012 X mg, tablet, orally, once daily for 2 weeks

  • DWP14012 X mg placeboDrug

    DWP14012 X mg placebo-matching tablet, orally, once daily for 2 weeks

  • DWP14012 Y mgDrug

    DWP14012 Y mg, tablet, orally, twice daily for 2 weeks

  • DWP14012 Y mg placeboDrug

    DWP14012 Y mg placebo-matching tablet, orally, twice daily for 2 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Improvement rate of gastric mucosal erosionTime frame: at 2 weeks after the IP administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hanyang University Medical Center

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.